Core Insights - HealthEquity Community Foundation announced a total of $50,000 in funding awarded to 20 nonprofit organizations in the summer 2025 grant cycle, supporting various operational activities including food, clothing, and medical care [1] - The foundation has increased funding across its core focus areas, with a notable 50% increase in support for mental health initiatives since the first funding round [3] - The foundation will welcome a new president, Stephanie Larsen, later this year, who has over a decade of experience at HealthEquity and a strong public health background [4] Funding and Support - The funding will assist vulnerable populations by providing free dental, vision, and medical care, addressing immense demand for these services [2] - The next grant cycle is currently open for eligible 501(c)(3) organizations to apply until September 30, 2025 [5] - The foundation plans to provide additional funding rounds twice each year, emphasizing its commitment to community wellness [6] Organizational Overview - HealthEquity administers HSAs and various consumer-directed benefits for over 17 million accounts, partnering with employers and benefits advisors to enhance healthcare consumer empowerment [7]

Core Insights - The HealthEquity Community Foundation has awarded a total of $50,000 in grants to 20 nonprofit organizations focused on physical and mental health, financial literacy, and basic needs [1][3] - The foundation has seen a 50% increase in funding for mental health initiatives since its first round of funding, reflecting its commitment to holistic community wellness [3] - A new leader, Stephanie Larsen, will take over as president later this year, succeeding Dale Miller, who has been instrumental in launching the foundation [4][5] Funding and Support - The funding will support various operational activities, including providing food, clothing, and expert medical care to vulnerable populations [1][2] - The next grant cycle is open for applications until September 30, 2025, encouraging eligible 501(c)(3) organizations to apply [5] Organizational Impact - The foundation aims to connect health and financial well-being, particularly among underserved groups, as it continues to grow and innovate [5] - HealthEquity administers HSAs and other consumer-directed benefits for over 17 million accounts, partnering with employers and benefits advisors to improve health outcomes [7][8]

Core Insights - Organon (OGN) is currently more attractive to value investors compared to HealthEquity (HQY) based on various financial metrics and Zacks Rank [3][7]. Valuation Metrics - OGN has a forward P/E ratio of 2.38, significantly lower than HQY's forward P/E of 24.60 [5]. - The PEG ratio for OGN is 0.90, while HQY's PEG ratio stands at 1.18, indicating OGN's better valuation relative to its expected earnings growth [5]. - OGN's P/B ratio is 3.23, compared to HQY's P/B ratio of 3.74, further supporting OGN's more favorable valuation [6]. Zacks Rank and Style Scores - OGN holds a Zacks Rank of 2 (Buy), indicating a stronger earnings outlook, while HQY has a Zacks Rank of 3 (Hold) [3]. - OGN has a Value grade of A, whereas HQY has a Value grade of C, reflecting OGN's superior valuation metrics [6].

Core Viewpoint - HealthEquity, Inc. plans to release its second quarter fiscal 2026 financial results on September 2, 2025, followed by a conference call for investors to discuss the results [1] Financial Results Announcement - The financial results will be released after the close of regular stock market trading hours on September 2, 2025 [1] - A conference call will be held at 4:30 p.m. Eastern Time on the same day to review the financial results [2] Upcoming Investor Conferences - HealthEquity management will present and meet with investors at several upcoming conferences: - Wells Fargo 2025 Healthcare Conference on September 3, 2025, at 8:00 a.m. Eastern Time [3] - Jefferies 2025 Fintech Conference on September 4, 2025, at 10:40 a.m. Eastern Time [4] - Morgan Stanley 23 Annual Global Healthcare Conference on September 8, 2025, at 10:45 a.m. Eastern Time [5] - Baird 2025 Global Healthcare Conference on September 9, 2025, at 2:00 p.m. Eastern Time [6] - Deutsche Bank's 2025 Healthcare Summit on September 10, 2025, with one-on-one meetings scheduled [7][8] Company Overview - HealthEquity administers health savings accounts (HSAs) and other consumer-directed benefits for over 17 million accounts [8] - The company collaborates with employers, benefits advisors, and health and retirement plan providers to empower healthcare consumers [8]

Core Insights - Zacks Premium offers tools for investors to enhance their stock market engagement and confidence through various resources like daily updates, research reports, and stock screens [1] Zacks Style Scores - Zacks Style Scores are indicators designed to help investors select stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum [2] - The Value Score focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Sales [3] - The Growth Score assesses a company's financial health and future potential through projected earnings and sales growth [4] - The Momentum Score identifies optimal times to invest based on price trends and earnings estimate changes [5] - The VGM Score combines the three Style Scores to highlight stocks with attractive value, growth potential, and positive momentum [6] Zacks Rank - The Zacks Rank is a proprietary model that utilizes earnings estimate revisions to guide investors, with 1 (Strong Buy) stocks achieving an average annual return of +23.62% since 1988, significantly outperforming the S&P 500 [7] - There are typically over 800 stocks rated 1 or 2, making it essential for investors to use Style Scores to narrow down their choices [8] - To maximize returns, investors should target stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [9] - Stocks with lower ranks, even with good Style Scores, may still face downward price pressure due to negative earnings outlooks [10] Company Spotlight: HealthEquity (HQY) - HealthEquity, based in Draper, UT, provides integrated healthcare account management solutions and is rated 2 (Buy) with a VGM Score of B [11] - The company is positioned well for growth, with a Growth Style Score of B and a projected year-over-year earnings growth of 19.6% for the current fiscal year [12] - Recent analyst revisions have increased the earnings estimate for fiscal 2026 by $0.11 to $3.73 per share, alongside an average earnings surprise of +12.4% [12]

Core Viewpoint - HealthEquity (HQY) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which have a strong correlation with near-term stock price movements [4][6]. - Rising earnings estimates for HealthEquity suggest an improvement in the company's underlying business, likely leading to increased stock prices [5][10]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with a proven track record of performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7][9]. - Only the top 20% of Zacks-covered stocks receive a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions [10]. HealthEquity's Earnings Estimates - HealthEquity is expected to earn $3.73 per share for the fiscal year ending January 2026, with no year-over-year change [8]. - Over the past three months, the Zacks Consensus Estimate for HealthEquity has increased by 8.8%, reflecting analysts' positive revisions [8].

Core Insights - The article compares GoodRx Holdings, Inc. (GDRX) and HealthEquity (HQY) to determine which stock is more attractive to value investors [1] - GDRX has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while HQY has a Zacks Rank of 3 (Hold) [3] Valuation Metrics - GDRX has a forward P/E ratio of 12.80, significantly lower than HQY's forward P/E of 27.57 [5] - The PEG ratio for GDRX is 1.15, while HQY's PEG ratio is 1.32, suggesting GDRX is more favorably valued considering expected earnings growth [5] - GDRX's P/B ratio is 2.64 compared to HQY's P/B of 4.2, further indicating GDRX's relative undervaluation [6] Value Grades - GDRX has earned a Value grade of B, while HQY has a Value grade of D, highlighting GDRX's superior valuation metrics [6] - The combination of solid earnings outlook and favorable valuation figures positions GDRX as the better value option currently [6]

Core Viewpoint - HealthEquity (HQY) shares have declined approximately 10.4% over the past month, underperforming the S&P 500, raising questions about the potential for a breakout or continued negative trend leading up to the next earnings release [1] Group 1: Earnings Report and Estimates - The consensus estimate for HealthEquity has increased by 8.01% over the past month, indicating a positive trend in estimates [2] - The stock has received a Zacks Rank 2 (Buy), suggesting expectations for above-average returns in the coming months [4] Group 2: VGM Scores - HealthEquity has a Growth Score of B and a Momentum Score of B, indicating strong performance in these areas [3] - The stock has a Value Score of C, placing it in the middle 20% for this investment strategy, contributing to an overall aggregate VGM Score of B [3]

Core Viewpoint - Growth investors are attracted to stocks with above-average financial growth, but identifying such stocks can be challenging due to inherent risks and volatility [1] Group 1: Company Overview - HealthEquity (HQY) is identified as a promising growth stock, supported by a favorable Growth Score and a top Zacks Rank [2] - The company provides services for managing health care accounts, making it a relevant choice for growth investors [3] Group 2: Earnings Growth - HealthEquity has a historical EPS growth rate of 19.1%, with projected EPS growth of 19.3% for the current year, significantly outperforming the industry average of 8.5% [5] Group 3: Cash Flow Growth - The year-over-year cash flow growth for HealthEquity stands at 25.9%, well above the industry average of -1.5% [6] - The company's annualized cash flow growth rate over the past 3-5 years is 19.3%, compared to the industry average of 7.6% [7] Group 4: Earnings Estimate Revisions - There has been a positive trend in earnings estimate revisions for HealthEquity, with the Zacks Consensus Estimate for the current year increasing by 9.2% over the past month [8] Group 5: Investment Potential - HealthEquity holds a Zacks Rank of 2 (Buy) and a Growth Score of B, indicating its potential as an outperformer and a solid choice for growth investors [10]

Core Viewpoint - Growth investors are focused on stocks with above-average financial growth, but identifying stocks that can fulfill their growth potential is challenging [1] Group 1: Company Overview - HealthEquity (HQY) is currently recommended as a growth stock due to its favorable Growth Score and top Zacks Rank [2] - The company has a historical EPS growth rate of 19.1%, with projected EPS growth of 15.8% this year, significantly higher than the industry average of 7.7% [5] Group 2: Financial Metrics - HealthEquity's year-over-year cash flow growth is 25.9%, outperforming the industry average of -1.5% [6] - The company's annualized cash flow growth rate over the past 3-5 years is 19.3%, compared to the industry average of 8% [7] Group 3: Earnings Estimates - There has been a positive trend in earnings estimate revisions for HealthEquity, with the Zacks Consensus Estimate for the current year increasing by 6.5% over the past month [8] - HealthEquity has earned a Growth Score of B and carries a Zacks Rank 2 due to positive earnings estimate revisions, indicating it is a potential outperformer for growth investors [10]